dsips DSI Announces New Employee Ownership Structure Developmental Services, Inc. | LinkedIn
Description
Inczefi, O
As we conclude, the dihexa peptide continues to be a promising candidate in the realm of neuropharmacology
Solitomab or MT-110 is a BiTE against EPCAM and CD3, which bridges between tumor cells and T cells, leading to lysis of tumor cells [196, 198]
After the withdrawal statement, results from other clinical trials on the use of bevacizumab in breast cancer were published
N., Dessypris, E
